Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial

Nasser K. Altorki, Zachary H. Walsh, Johannes C. Melms, Jeffery L. Port, Benjamin E. Lee, Abu Nasar, Cathy Spinelli, Lindsay Caprio, Meri Rogava, Patricia Ho, Paul J. Christos, Ashish Saxena, Olivier Elemento, Bhavneet Bhinder, Casey Ager, Amit Dipak Amin, Nicholas J. Sanfilippo, Vivek Mittal, Alain C. Borczuk, Silvia C. FormentiBenjamin Izar, Timothy E. McGraw

Research output: Contribution to journalComment/debatepeer-review

Abstract

Correction to: Nature Communications, published online 19 December 2023 In this article, the author name Silvia C. Formenti was incorrectly written as Sylvia C. Formenti. The original article has been corrected.

Original languageEnglish (US)
Article number225
Pages (from-to)225
JournalNature Communications
Volume15
Issue number1
DOIs
StatePublished - Jan 3 2024

ASJC Scopus subject areas

  • General Chemistry
  • General Biochemistry, Genetics and Molecular Biology
  • General Physics and Astronomy

Fingerprint

Dive into the research topics of 'Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial'. Together they form a unique fingerprint.

Cite this